A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525974-21-00

Enrollment

Registered

2026-08-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Coronary Artery disease, Heart Failure

Brief summary

Change from baseline in log-transformed IL-6

Detailed description

Change from baseline in log-transformed IL-6, Change from baseline in log-transformed hsCRP, Responder status (yes/no), defined as hsCRP <2 mg/L, Responder status (yes/no), defined as hsCRP <1 mg/L, Adverse events, and parameters from safety assessments, including vital signs, ECGs, and laboratory assessments (urine and blood) through the end of treatment / study (EOT/EOS)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in log-transformed IL-6	—

Secondary

Measure	Time frame
Change from baseline in log-transformed IL-6, Change from baseline in log-transformed hsCRP, Responder status (yes/no), defined as hsCRP <2 mg/L, Responder status (yes/no), defined as hsCRP <1 mg/L, Adverse events, and parameters from safety assessments, including vital signs, ECGs, and laboratory assessments (urine and blood) through the end of treatment / study (EOT/EOS)	—

Outcome results